DE60216090T2 - Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia - Google Patents

Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia Download PDF

Info

Publication number
DE60216090T2
DE60216090T2 DE60216090T DE60216090T DE60216090T2 DE 60216090 T2 DE60216090 T2 DE 60216090T2 DE 60216090 T DE60216090 T DE 60216090T DE 60216090 T DE60216090 T DE 60216090T DE 60216090 T2 DE60216090 T2 DE 60216090T2
Authority
DE
Germany
Prior art keywords
stress
acetyl
carnitine
rats
die
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60216090T
Other languages
German (de)
English (en)
Other versions
DE60216090D1 (de
Inventor
Sigma-Tau Ind. Farm. Riunite SpA Menotti CALVANI
Sigma-Tau Ind. Farm. Riunite SpA Luigi MOSCONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001RM000292A external-priority patent/ITRM20010292A1/it
Priority claimed from IT2001RM000319A external-priority patent/ITRM20010319A1/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE60216090D1 publication Critical patent/DE60216090D1/de
Application granted granted Critical
Publication of DE60216090T2 publication Critical patent/DE60216090T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60216090T 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia Expired - Fee Related DE60216090T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITRM20010029 2001-05-29
IT2001RM000292A ITRM20010292A1 (it) 2001-05-29 2001-05-29 Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
IT2001RM000319A ITRM20010319A1 (it) 2001-06-08 2001-06-08 Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.
ITRM20010031 2001-06-08
PCT/IT2002/000339 WO2002096411A1 (en) 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Publications (2)

Publication Number Publication Date
DE60216090D1 DE60216090D1 (de) 2006-12-28
DE60216090T2 true DE60216090T2 (de) 2007-05-31

Family

ID=26332845

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216090T Expired - Fee Related DE60216090T2 (de) 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia

Country Status (16)

Country Link
US (2) US20040171685A1 (https=)
EP (1) EP1399143B1 (https=)
JP (1) JP2004532867A (https=)
KR (1) KR20040003031A (https=)
AT (1) ATE345124T1 (https=)
CA (1) CA2448246A1 (https=)
CZ (1) CZ20033222A3 (https=)
DE (1) DE60216090T2 (https=)
DK (1) DK1399143T3 (https=)
ES (1) ES2275881T3 (https=)
HU (1) HUP0400007A2 (https=)
MX (1) MXPA03010920A (https=)
PL (1) PL367628A1 (https=)
PT (1) PT1399143E (https=)
SK (1) SK15862003A3 (https=)
WO (1) WO2002096411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
CA3238205A1 (en) 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani

Also Published As

Publication number Publication date
CZ20033222A3 (cs) 2004-06-16
ATE345124T1 (de) 2006-12-15
ES2275881T3 (es) 2007-06-16
CA2448246A1 (en) 2002-12-05
US20060148896A1 (en) 2006-07-06
DE60216090D1 (de) 2006-12-28
DK1399143T3 (da) 2007-03-26
WO2002096411A1 (en) 2002-12-05
KR20040003031A (ko) 2004-01-07
PL367628A1 (en) 2005-03-07
EP1399143A1 (en) 2004-03-24
HUP0400007A2 (hu) 2004-04-28
SK15862003A3 (sk) 2004-06-08
US20040171685A1 (en) 2004-09-02
EP1399143B1 (en) 2006-11-15
MXPA03010920A (es) 2004-02-27
JP2004532867A (ja) 2004-10-28
PT1399143E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
DE69129115T2 (de) Neues verfahren zur behandlung von depression
CH653891A5 (de) Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier.
DE3883743T2 (de) Aminosäuren, nützlich bei Leberstörungen.
DE1792295B1 (de) Pharmazeutisches Praeparat enthaltend 1-Aminomethyladamantan
DE3875867T2 (de) Kalziumzusaetze.
DE3119460A1 (de) Pharmazeutische zusammensetzung aus l-karnitin und/oder l-acylkarnitin und verwendung der zusammensetzung gegen diabetes mellitus bei jugendlichen
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE60103055T2 (de) Nahrungsergänzung zur verbesserung des muskelenergiestoffwechsels, enthaltend alkanoyl-carnitine und ribose
DE2335215A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE60216090T2 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
DE69413637T2 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
DE60124516T2 (de) Kombination des lezithins mit ascorbinsäure
DE3609005A1 (de) Pharmazeutische zusammensetzungen mit metabolischer aktivitaet
DE2525064C2 (de) Arzneimittel mit Antiparkinson-Wirkung
DE68903448T2 (de) Pharmazeutische und/oder diaetetische zusammensetzungen mit gehalt an l-carnitin und l-lysin.
DE60020833T2 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag
EP1461042A1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60213237T2 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
EP0018550B1 (de) Mittel zur Behandlung von Muskelerkrankungen
AT412381B (de) Kombinations-präparat, enthaltend mineralstoffe, vitamine, kohlenhydrate und aminosäuren
DE1617508C3 (de) Antidepressive Mittel
DE2729530C3 (de) Verwendung von 4-Methyl-l-homopiperazindithiocarbonsäure und deren Salzen
DE10160485A1 (de) Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion
DE2033629C3 (de) Oral verabreichbares Mittel zur Erniedrigung des Serum-Lipidspiegels bei Menschen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee